Vertex Sells Legacy Oncology Portfolio To German Merck
Vertex Pharmaceuticals has sold off its oncology portfolio, comprised of six molecules across four early stage programs, to Merck of Germany for $230m and future royalties on sales – a low price tag in the immune-oncology deal spree arena.
You may also be interested in...
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.